The recent approval of the first oral fecal-derived microbiota therapy to prevent the recurrence of Clostridioides difficile (C. diff) infection in patients was welcome news for physicians who've struggled under the weight of having too few treatment options for the prevention of C. diff recurrence.
The product, developed by Massachusetts-based Seres Therapeutics and marketed as Vowst, was approved by the U.S. Food and Drug Administration on April 26. It is approved for use in adults who have already been treated with antibiotics for a recurrent infection with C. diff bacteria.
This is the first oral treatment for the prevention of C. diff recurrence and is designed to be delivered in four capsules taken daily for 3 days.
Vowst is the second therapy derived from human stool to be approved for the indication in less than 6 months.
